NTLA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Intellia Therapeutics Inc (NTLA) is a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock has positive regulatory developments, bullish technical indicators, and strong analyst upgrades. Despite insider selling and financial losses, the long-term growth potential in gene editing and favorable FDA updates make it a compelling investment.
The technical indicators are bullish. The MACD histogram is positive at 0.155, suggesting upward momentum. The RSI is neutral at 54.584, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot point (13.892) with resistance levels at 14.964 and 15.625, indicating potential for further upside.
The FDA has lifted clinical holds on the MAGNITUDE Phase 3 studies, allowing enrollment to resume. Analysts have upgraded the stock and raised price targets significantly, citing increased probability of success in key trials. Revenue growth of 78.79% YoY in Q4 2025 also reflects strong operational progress.
Insider selling has surged by 2235.78% in the last month, which could signal a lack of confidence from company insiders. Additionally, the company reported a net income loss of -$95.79 million in Q4 2025, with EPS dropping by -34.65% YoY, indicating financial challenges.
In Q4 2025, revenue increased by 78.79% YoY to $23.02 million, showing strong top-line growth. However, net income dropped to -$95.79 million, down -25.69% YoY, and EPS fell to -0.83, down -34.65% YoY. Gross margin remained stable at 100%.
Analysts are bullish on NTLA, with several upgrades and price target increases following the FDA's decision to lift clinical holds. Notable upgrades include JonesResearch upgrading to Buy with a $29 price target and H.C. Wainwright raising the target to $30. Analysts view the resolution of regulatory issues as a major positive catalyst for the stock.
